Latest fromPacific Edge Biotechnology Ltd
Market close: NZ sharemarket ends roller coaster year
The 'damp end' to the year is not just outside, but in the sharemarket too.
US contractor upholds Pacific Edge’s Medicare ban
Pacific Edge has the right to respond to the new Novitas declaration.
Market close: Pacific Edge’s darkest trading day in two decades
The NZ sharemarket fell more than 1 per cent today.
Markets with Madison: Construction slowdown hits suppliers
Metroglass is facing a challenge and Pacific Edge has a Medicare problem.
Cyclone and storms hit Tower half-year result; Pacific Edge’s revenue soars
Tower reports half-year net loss, while profit eludes Pacific Edge.
NZ shares finish flat but retail and Ryman stocks flourish
The New Zealand sharemarket finished the week on a subdued note.
Pacific Edge now confirms capital raise
It will use the money to accelerate its growth in the US market.
Pacific Edge share price drops after ASX announcement withdrawn
Pacific Edge shares fell after a statement about a capital raise was withdrawn by the ASX.
Pacific Edge shares climb on Kaiser addition
US healthcare giant takes up another PEB product.
Acing the test: Pacific Edge boss has the last laugh
Pacific Edge CEO David Darling explains how it became a billion dollar company.
Pacific Edge shares spike after gaining cover from US insurance giant
The NZX-listed cancer diagnostics company will have its "Cxbladder" tests covered.
Pacific Edge to be included in S&P/NZX50 index
Pacific Edge shares rallied following the news.
Pacific Edge on a roll, but still no sign of a profit
Pacific Edge has been on a roll since signing a deal with Kaiser Permanente in the US.
US fund takes stake in diagnostics firm Pacific Edge
Pacific Edge said Manchester Management Company will take a 1.7 per cent stake in company.
Pacific Edge undertakes $8m share placement
Pacific Edge has undertaken an $8 million share placement to institutional and other select investors in New Zealand in order to shore up its balance sheet.
Pacific Edge first-half loss widens
Pacific Edge widened its first-half loss, spending more on the roll-out of products across America.
Pacific Edge seeks $35.3M to fund US growth
Pacific Edge is planning a $35.3m offer at a 6.2 per cent discount to fund its US growth strategy.
F&P at record on higher profit
New Zealand shares rose as Fisher & Paykel Healthcare advanced to a record after lifting its annual profit guidance. Xero fell as its first-half results showed a slower pace of growth.
NZX's worst shares of 2014 (+graphic)
What are the top 10 worst performing shares of 2014 so far? Find out with a graphic showing the biggest losers.
Tech stocks snap two-day slide
New Zealand tech stocks led the local market higher in morning trade, snapping a two-day decline as investors returned to tech and biotech stocks.
Local tech stocks take another plunge
Pacific Edge shares slumped to a five-month low and Xero plunged again as as the local stock market joined a global sell-off amid concerns high-growth companies may struggle to convert sales into profits.
Wild week for Pacific Edge
Pacific Edge chief executive David Darling is the first to admit even he didn't envisage his company's product - bladder cancer test Cxbladder - succeeding globally so quickly.